Infant botulism is rare, but its earliest manifestations can look deceptively ordinary.

Constipation, slower feeding, a weaker or altered cry, reduced facial expression, and loss of head control may precede the more recognizable pattern of hypotonia, bulbar weakness, descending paralysis, and respiratory difficulty.

Infant botulism occurs when spores from Clostridium botulinum or related neurotoxin-producing species are swallowed, temporarily colonize the large intestine, and produce botulinum neurotoxin inside the infant. This differs from classic foodborne botulism, in which preformed toxin is consumed. [1]

The clinical diagnosis matters because treatment should not wait for laboratory confirmation. When infant botulism is suspected, clinicians should promptly contact the California Department of Public Health Infant Botulism Treatment and Prevention Program (IBTPP), which provides 24/7 consultation and coordinates BabyBIG®. [2]

This Blog was updated again in October 2026 because FDA issued new lot-specific dosage and administration instructions for BabyBIG Lot 8. The change affects the dose and supplied infusion filter for that lot and should not be generalized automatically to previous or future lots without checking current shipment instructions. [5]

Key Takeaways

• Infant botulism often begins gradually, with constipation, poor feeding, weak cry, reduced facial expression, or loss of head control.

• Progressive cranial-nerve and bulbar weakness can lead to hypotonia, descending flaccid paralysis, respiratory weakness, and respiratory failure. [1]

• Diagnosis begins clinically. Do not wait for stool-test confirmation before obtaining specialist consultation and initiating treatment when the clinical assessment supports infant botulism.

• BabyBIG is the FDA-approved human botulism immune globulin for infant botulism caused by toxin types A and B in patients younger than one year.

• Early BabyBIG administration reduces hospital stay and major measures of illness burden. [3] [4]

• October 23, 2026: FDA specified a dose of 0.4 mL/kg (20 mg/kg) for BabyBIG Lot 8, given as a single IV infusion, with the 0.2-micron filter supplied with the shipment. [5]

• The Lot 8 instructions should not be turned into a universal rule for every BabyBIG lot. Clinicians and pharmacists should verify the current lot-specific materials supplied with the product and consult IBTPP when needed.

• BabyBIG does not immediately reverse toxin already bound at nerve endings, so respiratory and nutritional support remain essential.

• The 2026 Nara Organics outbreak is over, but recalled formula may still remain in homes because of its shelf life. Four confirmed cases were reported; all four infants were hospitalized and no deaths occurred. [7]

• FDA and CDC now report evidence indicating a common contamination source linking the Nara outbreak with the earlier ByHeart outbreak, but the precise root cause has not been established. [8]

What Is Infant Botulism?

Infant botulism is an intestinal toxemia.

Swallowed spores can germinate and colonize the immature large intestine. The organisms then produce botulinum neurotoxin, which reaches cholinergic nerve terminals and disrupts acetylcholine release. The result is progressive neuromuscular weakness. [1]

Typical findings include:

• constipation;

• poor feeding;

• weak or altered cry;

• diminished suck and gag reflexes;

• ptosis;

• reduced facial expression;

• sluggish pupils;

• loss of head control;

• hypotonia;

• descending weakness;

• respiratory difficulty or respiratory arrest.

Constipation is common and can be an early clue, but it is not diagnostic by itself. Many infants become constipated for unrelated reasons.

Infant Botulism Is Not the Same as Foodborne Botulism

The distinction is mechanistic.

In infant botulism, the infant ingests spores, which colonize the intestine and produce toxin after ingestion.

In classic foodborne botulism, the patient ingests preformed toxin already present in food.

That difference explains why exposure questions in infant botulism focus on possible spore sources, the infant's age, environmental exposures, honey, and—during a product investigation—specific formula products or lots.

What Are the Early Symptoms of Infant Botulism?

The disease can initially appear subtle.

Parents may notice that an infant:

• has not passed stool normally;

• feeds more slowly or tires during feeds;

• has difficulty maintaining suction;

• sounds quieter or different when crying;

• seems less expressive;

• cannot hold the head up as well as before;

• appears unusually floppy or weak.

As neuromuscular weakness progresses, swallowing and airway protection can become impaired. Respiratory muscles can also weaken.

The pattern and progression of symptoms are more informative than any single finding. [1]

When Should Parents Seek Emergency Medical Care?

Immediate medical assessment is appropriate when an infant develops concerning weakness, feeding difficulty, swallowing problems, loss of head control, abnormal breathing, markedly reduced facial movement, or another progressive neurologic change.

Respiratory deterioration can occur as the disease progresses.

Parents should not wait for every “classic” sign to appear before seeking care.

This is particularly important for an infant who recently consumed a product involved in an active or recent botulism recall.

What Else Can Look Like Infant Botulism?

Infant botulism can resemble several neurologic, neuromuscular, infectious, and metabolic conditions.

Important alternatives include:

• spinal muscular atrophy;

• Guillain–Barré syndrome;

• myasthenic disorders;

• sepsis;

• meningitis or encephalitis;

• metabolic disease;

• electrolyte abnormalities;

• drug or toxin exposure.

The combination of progressive cranial-nerve dysfunction, bulbar weakness, hypotonia, and descending paralysis makes botulism particularly important to consider.

For a clinical example, see Case Study: An 8-Week-Old Infant with Weak Cry, Hypotonia, and Respiratory Distress.

How Is Infant Botulism Diagnosed?

The initial diagnosis is clinical.

CDC advises clinicians who suspect infant botulism to seek immediate case consultation from IBTPP. In the United States, the clinician line is available 24 hours a day at 510-231-7600. [2]

If the clinical consultation supports infant botulism, treatment should begin as soon as possible.

Do not wait for laboratory confirmation before treating a clinically supported case. [1]

Laboratory Confirmation

Stool testing can identify botulinum toxin, toxigenic organisms, or both.

Testing is valuable for confirming the diagnosis, epidemiology, surveillance, and outbreak investigation. However, results may take time, and a negative result does not necessarily exclude the diagnosis.

BabyBIG administration does not eliminate botulinum toxin or organisms from the intestinal lumen, so stool specimens may be collected before or after antitoxin treatment.

What Is BabyBIG?

BabyBIG®, or Botulism Immune Globulin Intravenous (Human), is a human-derived immunoglobulin product containing neutralizing antibodies against botulinum neurotoxins.

It is FDA approved for treatment of infant botulism caused by toxin types A and B in patients younger than one year.

BabyBIG neutralizes toxin that remains available in the circulation.

It does not remove toxin already bound to cholinergic nerve terminals and does not instantly restore neuromuscular function.

This explains why an infant can remain weak—or temporarily appear to worsen—after appropriate treatment while nerve terminals recover.

Why Early BabyBIG Treatment Matters

The strongest treatment evidence comes from a randomized, double-blind, placebo-controlled trial involving 122 infants with laboratory-confirmed infant botulism.

Mean hospital stay fell from 5.7 weeks with placebo to 2.6 weeks with BIG-IV. Treatment also reduced time in intensive care, duration of mechanical ventilation, and tube or intravenous feeding. [3]

Post-licensure data later evaluated 1,192 U.S. patients treated from 2003 through 2015.

Mean hospital stay among treated infants was 2.2 weeks, compared with 5.7 weeks in the historical pivotal-trial placebo group. The greatest reduction occurred when treatment was given during the first three hospital days. [4]

These data support early treatment.

They do not mean that BabyBIG immediately reverses established paralysis or eliminates the need for respiratory, feeding, and intensive supportive care.

October 23, 2026 — BabyBIG Lot 8 Administration Update

FDA issued a specific dosage and administration communication for BabyBIG Lot 8 on October 23, 2026. [5]

For Lot 8, FDA states:

FDA explains that manufacturing changes involving recombinant botulinum vaccine A/B as the source-plasma booster immunogen resulted in higher antibody titers against type A and B botulinum neurotoxins. Those higher titers, together with supply considerations, support the Lot 8 dose adjustment. [5]

How This Differs From the Earlier Prescribing Information

The 2021 prescribing information listed:

• 1.0 mL/kg (50 mg/kg) as the recommended total dose;

• a single IV infusion;

• an 18-micron in-line or syringe-tip sterile disposable filter. [6]

FDA's October 23 communication specifies that, for Lot 8, the dose is 0.4 mL/kg (20 mg/kg) and the filter supplied with the shipment is 0.2 micron. [5]

Do Not Generalize the Lot 8 Instructions

The Lot 8 communication is a lot-specific administration update.

It should not be rewritten as:

“The universal BabyBIG dose is now 20 mg/kg and all BabyBIG must be given through a 0.2-micron filter.”

Instead, clinicians and pharmacists should:

• identify the BabyBIG lot actually supplied;

• follow the dose and filter instructions accompanying that shipment;

• review current IBTPP guidance;

• contact the Infant Botulism Treatment and Prevention Program when there is uncertainty.

The IBTPP clinician consultation line remains available 24/7/365 at 510-231-7600. [2]

BabyBIG Does Not Replace Supportive Care

Infants may still require intensive supportive treatment while neuromuscular function recovers.

Depending on severity, care can include:

• close respiratory assessment;

• oxygenation and ventilatory support;

• airway protection and mechanical ventilation when required;

• aspiration prevention;

• feeding and nutritional support;

• hydration and electrolyte monitoring;

• secretion management;

• prevention of complications associated with prolonged weakness and hospitalization.

Maintaining an acceptable oxygen saturation does not by itself prove that ventilation is adequate in a child developing respiratory-muscle weakness.

Supportive-care decisions should remain individualized to the infant's respiratory and neurologic status. This October 2026 update does not change established airway or critical-care principles.

How Long Does Recovery Take?

Recovery is usually gradual.

Some infants improve relatively quickly after early treatment, while others require prolonged feeding support, respiratory support, or hospitalization.

BabyBIG limits progression from toxin that remains unbound, but recovery from already established neuromuscular blockade depends on regeneration of functional nerve terminals.

Most infants who survive the acute illness are expected to recover neurologic function.

Can Infant Botulism Be Prevented?

Not every case has an identifiable preventable exposure.

Environmental spores are naturally present in soil and dust, so complete prevention is not possible.

Avoid Honey Before 12 Months

Honey remains the best-established specific preventable exposure.

Honey and honey-containing products should not be given to infants younger than 12 months.

Heating, cooking, or pasteurization should not be relied upon to remove the risk from botulinum spores.

Why Formula Recalls Require a Different Response

Powdered infant formula is not sterile, but routine formula-preparation guidance should not be confused with recall guidance.

When a specific product is recalled because of a potential serious microbiologic hazard:

• stop using the recalled product;

• do not attempt to make it safe by boiling or heating;

• do not mix it with non-recalled formula;

• do not donate or resell it;

• follow current FDA/CDC disposal and cleaning recommendations.

The correct action is product avoidance, not modified preparation.

Current Status of the 2026 Nara Organics Outbreak

The previous version of this Blog reflected an earlier phase of the investigation.

That status is now outdated.

CDC declared the Nara Organics infant botulism outbreak over on August 27, 2026. The final outbreak summary includes:

• 4 confirmed cases;

• cases in California, Pennsylvania, and Washington;

• 4 hospitalizations;

• 0 deaths. [7]

All Nara Organics Whole Milk Organic Infant Formula had been recalled.

Because powdered formula can remain in homes for a long time, CDC continues to advise families who still possess recalled Nara formula not to use it and to throw it away. Items and surfaces that contacted recalled formula should be washed with hot soapy water or in a dishwasher. [7]

Symptoms can take several weeks to develop. CDC advises parents whose infants consumed recalled Nara formula to watch for symptoms for one month after the last consumption.

What the Nara–ByHeart Investigation Now Shows

The evidence has strengthened since the early July 2026 investigation.

FDA reports that whole-genome sequencing from one Nara-associated clinical sample genetically matched:

• a clinical isolate from the earlier ByHeart outbreak;

• a powdered infant formula base sample from the ByHeart investigation;

• four samples from unopened ByHeart formula cans. [8]

FDA also identified shared supply-chain elements between the Nara and ByHeart investigations.

The agency now states that the genomic findings and supply-chain commonalities indicate a common source of contamination between the two outbreaks.

That is stronger than the evidence available in July 2026.

However, it still does not establish the exact point at which contamination occurred.

FDA's root-cause investigation remains focused on ingredients, supply-chain controls, powdered-milk surveillance, and prevention activities. [8]

For the current supply-chain and regulatory context, see FDA Calls for Stronger Infant Formula Safeguards After Botulism Outbreaks. FDA Calls for Stronger Infant Formula Safeguards After Botulism Outbreaks

What Did the ByHeart Outbreak Add?

The earlier ByHeart outbreak demonstrated how clinical surveillance, formula testing, epidemiology, and whole-genome sequencing can identify an unusual common-source infant botulism outbreak.

A 2026 NEJM Evidence report described 51 suspected or confirmed cases with ByHeart exposure identified across 19 states as of December 10, 2025. [9]

The subsequent public-health classification evolved as investigations were completed, illustrating why outbreak counts and case definitions should be tied to a specific reporting date.

The ByHeart evidence does not change the core bedside rule:

suspected infant botulism is a clinical emergency, and treatment should not wait for definitive laboratory confirmation.

Guidance for Clinicians

When infant botulism is suspected:

1. recognize the clinical pattern of progressive cranial-nerve, bulbar, and descending weakness;

2. assess respiratory function carefully;

3. contact IBTPP promptly at 510-231-7600;

4. begin BabyBIG when consultation supports the diagnosis;

5. do not delay treatment while waiting for stool testing;

6. report suspected cases through appropriate public-health channels;

7. verify the current BabyBIG lot and lot-specific administration instructions before preparation and infusion.

For Lot 8, the October 23, 2026 FDA instructions specify 0.4 mL/kg (20 mg/kg) as a single IV infusion and use of the supplied 0.2-micron filter. [5]

What Is Established and What Remains Uncertain?

Established

• Infant botulism is an intestinal toxemia caused by botulinum neurotoxin produced after intestinal colonization.

• Clinical recognition precedes laboratory confirmation.

• Early BabyBIG reduces hospital stay and several measures of disease burden.

• BabyBIG does not immediately reverse established paralysis.

• Honey should not be given to infants younger than 12 months.

• The Nara outbreak is over.

• The final Nara outbreak count was four confirmed cases, all hospitalized, with no deaths.

• Current evidence indicates a common contamination source connecting the Nara and ByHeart outbreaks.

• BabyBIG Lot 8 has specific FDA dosage and filter instructions dated October 23, 2026.

Still Unresolved or Lot-Dependent

• The precise contamination point responsible for the Nara–ByHeart common source has not been established.

• The Lot 8 dose/filter instructions should not be extrapolated automatically to other lots without verifying current official materials.

• Future BabyBIG lots may carry revised shipment-specific instructions.

• The exact timing and degree of clinical recovery after treatment vary substantially among infants.

The Bottom Line

Infant botulism can begin quietly and progress rapidly.

Constipation, poor feeding, weak cry, reduced facial movement, and loss of head control can precede profound hypotonia and respiratory weakness. Diagnosis is primarily clinical, and expert consultation plus treatment should not be delayed while waiting for laboratory confirmation.

BabyBIG has strong human clinical evidence supporting early treatment. But correct administration now requires attention not only to the diagnosis, but also to which BabyBIG lot has been supplied.

For Lot 8, FDA's October 23, 2026 communication specifies 0.4 mL/kg (20 mg/kg) as a single IV infusion using the supplied 0.2-micron filter. Those instructions supersede the older prescribing-information dose and filter for this lot; they should not be generalized automatically beyond it. [5]

Formula-safety information has also matured. The Nara outbreak is over, but recalled products should still not be used, and FDA continues post-outbreak work because genomic and supply-chain evidence indicates a common contamination source linking Nara and ByHeart while the precise root cause remains unresolved.

The practical priorities remain the same: recognize progressive weakness early, obtain specialist consultation quickly, administer the correct BabyBIG product according to current lot-specific instructions, support respiration and feeding as needed, and follow official recall guidance precisely.

Frequently Asked Questions

1. What is usually the first sign of infant botulism?

Constipation is common and may be early, but poor feeding, weak cry, reduced facial movement, or loss of head control may be noticed first. The progression and combination of findings are more informative than any single symptom.

2. Should clinicians wait for a positive stool test before giving BabyBIG?

No. When the clinical evaluation and IBTPP consultation support infant botulism, treatment should begin as soon as possible. Laboratory confirmation should not delay treatment. [1]

3. What is the BabyBIG Lot 8 dose?

FDA's October 23, 2026 Lot 8 communication specifies 0.4 mL/kg (20 mg/kg) as a single IV infusion. The supplied 0.2-micron filter should be used for Lot 8. Clinicians and pharmacists should verify the shipment-specific instructions rather than extrapolate those instructions automatically to other lots. [5]

4. Does BabyBIG immediately reverse paralysis?

No. BabyBIG neutralizes toxin that has not yet bound to nerve endings. Neuromuscular weakness caused by toxin already bound to nerve terminals can persist while the nervous system recovers.

5. Can recalled formula be made safe by boiling it?

No. A recalled infant-formula product should not be used. Heating or changing the preparation method does not replace FDA or CDC recall instructions.

6. Is the Nara infant-botulism outbreak still active?

No. CDC declared the outbreak over on August 27, 2026. Four confirmed cases were reported, all four infants were hospitalized, and no deaths occurred. Recalled Nara formula should still not be used if it remains in a household. [7]